Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Mathew

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Journal of the National Cancer Institute|June 8, 2006
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancerSun-Jin Kim, Hisanori Uehara, Sertac Yazici, et al.
The Journal of Urology|November 18, 2008
Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancerPaul Mathew, Louis L Pisters, Christopher G Wood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortiumJonathan E Rosenberg, Charles J Ryan, Vivian K Weinberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancerSue-Hwa Lin, Yu-Chen Lee, Michel B Choueiri, et al.
Cancer|August 27, 2014
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancerMehmet Asim Bilen, Marcella M Johnson, Paul Mathew, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 13, 2015
Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptorsJami Mandelin, Marina Cardó-Vila, Wouter H P Driessen, et al.
Clinical Genitourinary Cancer|February 14, 2009
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical researchMichael J Morris, Ethan M Basch, George Wilding, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2013
Platinum-based chemotherapy for variant castrate-resistant prostate cancerAna M Aparicio, Andrea L Harzstark, Paul G Corn, et al.
Investigational New Drugs|March 26, 2010
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortiumDeborah A Bradley, Stephanie Daignault, Charles J Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancerMary-Ellen Taplin, Meredith M Regan, Yoo-Joung Ko, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Journal of the National Cancer Institute|June 8, 2006
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancerSun-Jin Kim, Hisanori Uehara, Sertac Yazici, et al.
The Journal of Urology|November 18, 2008
Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancerPaul Mathew, Louis L Pisters, Christopher G Wood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortiumJonathan E Rosenberg, Charles J Ryan, Vivian K Weinberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancerSue-Hwa Lin, Yu-Chen Lee, Michel B Choueiri, et al.
Cancer|August 27, 2014
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancerMehmet Asim Bilen, Marcella M Johnson, Paul Mathew, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 13, 2015
Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptorsJami Mandelin, Marina Cardó-Vila, Wouter H P Driessen, et al.
Clinical Genitourinary Cancer|February 14, 2009
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical researchMichael J Morris, Ethan M Basch, George Wilding, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2013
Platinum-based chemotherapy for variant castrate-resistant prostate cancerAna M Aparicio, Andrea L Harzstark, Paul G Corn, et al.
Investigational New Drugs|March 26, 2010
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortiumDeborah A Bradley, Stephanie Daignault, Charles J Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancerMary-Ellen Taplin, Meredith M Regan, Yoo-Joung Ko, et al.
Pageof 7